• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19.将直接病毒细胞病变假说应用于针对 COVID-19 的药物试验设计。
Daru. 2020 Dec;28(2):813-814. doi: 10.1007/s40199-020-00368-3. Epub 2020 Aug 15.
2
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.具有体外抗病毒活性和免疫调节作用的半胱胺有可能成为治疗 COVID-19 的重新定位药物候选物。
Cells. 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052.
3
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.设计治疗策略以对抗严重急性呼吸综合征冠状病毒 2 型疾病：COVID-19。
Drug Dev Res. 2021 Feb;82(1):12-26. doi: 10.1002/ddr.21720. Epub 2020 Jul 30.
4
Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.针对 SARS-CoV-2 细胞进入机制的靶向治疗策略：体外和体内研究的系统评价。
J Cell Physiol. 2021 Apr;236(4):2364-2392. doi: 10.1002/jcp.30032. Epub 2020 Sep 9.
5
Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.重新定位药物以应对 COVID-19 大流行——一个洞察。
Curr Pharm Biotechnol. 2021;22(2):192-199. doi: 10.2174/1389201021999200820155927.
6
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响：一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
7
Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.调整 ACE/ACE2 失衡治疗 COVID-19 肺部病变的科学假说。
Cardiovasc Toxicol. 2021 Jun;21(6):498-503. doi: 10.1007/s12012-021-09649-y. Epub 2021 Apr 9.
8
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.尼他唑胺联合阿扎那韦/利托那韦治疗中重度 COVID-19（NACOVID）的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 4;22(1):3. doi: 10.1186/s13063-020-04987-8.
9
Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.小分子药物治疗 COVID-19 的发现：临床研究综述。
Mini Rev Med Chem. 2021;21(12):1431-1456. doi: 10.2174/1389557521666201228145755.
10
Antiviral Effect of Budesonide against SARS-CoV-2.布地奈德对 SARS-CoV-2 的抗病毒作用。
Viruses. 2021 Jul 20;13(7):1411. doi: 10.3390/v13071411.

引用本文的文献

1
TB and HIV surveillance amid COVID-19 pandemic.新冠疫情期间的结核病和艾滋病监测
Indian J Sex Transm Dis AIDS. 2022 Jan-Jun;43(1):85-86. doi: 10.4103/ijstd.ijstd_98_20. Epub 2022 Jun 7.
2
Association of systemic complications with mortality in coronavirus disease of 2019: A cohort study on intensive care unit patients.2019冠状病毒病全身并发症与死亡率的关联：一项针对重症监护病房患者的队列研究
J Res Med Sci. 2022 Apr 15;27:34. doi: 10.4103/jrms.JRMS_1213_20. eCollection 2022.

本文引用的文献

1
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.ABL1 定向抑制剂治疗 CML：疗效、耐药及未来展望。
Anticancer Res. 2020 May;40(5):2457-2465. doi: 10.21873/anticanres.14215.
2
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.中国 26 例 COVID-19 死亡患者的肾脏组织病理分析。
Kidney Int. 2020 Jul;98(1):219-227. doi: 10.1016/j.kint.2020.04.003. Epub 2020 Apr 9.
3
Likelihood of survival of coronavirus disease 2019.2019冠状病毒病的生存可能性。
Lancet Infect Dis. 2020 Jun;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Epub 2020 Mar 30.
4
Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.靶向内吞途径和自噬过程作为 COVID-19 的一种新治疗策略。
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731. doi: 10.7150/ijbs.45498. eCollection 2020.
5
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究：中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
6
Insights from nanomedicine into chloroquine efficacy against COVID-19.纳米医学对氯喹治疗 COVID-19 疗效的启示。
Nat Nanotechnol. 2020 Apr;15(4):247-249. doi: 10.1038/s41565-020-0674-9.
7
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.鉴定 2019 新型冠状病毒的受体结合域（RBD）：作为病毒附着抑制剂和疫苗开发 RBD 蛋白的意义。
Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.
8
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
9
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
10
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.2019-nCoV 对口腔黏膜上皮细胞 ACE2 受体的高表达。
Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.

将直接病毒细胞病变假说应用于针对 COVID-19 的药物试验设计。

The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19.

机构信息

Shiraz University of Medical Sciences, Shiraz, Iran.

School of Medicine, University of Central Lancashire, Preston, England.

出版信息

Daru. 2020 Dec;28(2):813-814. doi: 10.1007/s40199-020-00368-3. Epub 2020 Aug 15.

DOI:10.1007/s40199-020-00368-3
PMID:32803688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7429091/
Abstract

COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown to be the cellular host receptor for SARS-CoV-2. It might be the key to explain the pathogenesis of systemic complications with a focus on the direct viral cytopathic hypothesis. Different medications tend to show up in many in vitro drug screens. However, more trials are needed to translate their application into in vivo efficacy.

摘要

新型冠状病毒肺炎（COVID-19）在全球范围内造成了许多死亡。合并凝血病和急性呼吸窘迫综合征（ARDS）的全身并发症是 COVID-19 死亡的主要原因。该疾病的发病机制可以用两种理论来解释，即直接病毒细胞病变和全身炎症级联反应。已证实血管紧张素转换酶 2（ACE-2）是 SARS-CoV-2 的细胞宿主受体。它可能是解释全身并发症发病机制的关键，重点是直接病毒细胞病变假说。不同的药物在许多体外药物筛选中都有表现。然而，需要更多的试验将其应用转化为体内疗效。